Drug: CDX-110 (PF-04948568)
Abstract No.2014Indication: Glioblastoma (brain tumor) Clinical Trial: Interim data for ACT III: Phase II trial of PF-04948568 (CDX-110) in combination with temozolomide in patients with glioblastoma (GBM). Presentation Time: Saturday, June 5. Poster session. Notes:Thursday's research abstract reports efficacy results on the first 40 patients enrolled. Twenty-eight of 40 patients, or 70%, are progression free at 5.5 months of follow up. One patient reported a serious hypersensitivity reaction to the CDX-110 injections that required discontinuation from the study. The abstract also states that an additional, placebo-controlled study of CDX-110 will likely be required. Celldex's CDX-110, partnered with Pfizer, is engineered to activate a patient's immune system to fight cancer. Interest in so-called cancer "vaccines" is increasing as Dendreon (DNDN) awaits FDA approval of its prostate cancer immunotherapy Provenge.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts